NCT06743438View on ClinicalTrials.gov

Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

640

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

September 30, 2029

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Tenofovir Amibufenamide（TMF）

Once-daily oral dose of 25 mg TMF were maintained in all participants

Trial Locations (1)

510060

Nanfang Hospital, Southern Medical University, Guangzhou

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

NCT06743438 - Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB | Biotech Hunter | Biotech Hunter